Sofia RSV FIA Field Study
NCT01734668 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2468
Last updated 2013-02-07
Summary
The objective of this study is to demonstrate the clinical performance of the Sofia RSV FIA with specimens from symptomatic pediatric subjects who are less than nineteen (19) years of age.
Conditions
Interventions
- DEVICE
-
In Vitro Diagnostic device to aid in diagnosis
Sponsors & Collaborators
-
Quidel Corporation
lead INDUSTRY
Principal Investigators
-
John D Tamerius, PhD · Quidel Corporation
Eligibility
- Max Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-03-31
- Primary Completion
- 2013-01-31
- Completion
- 2013-01-31
Countries
- United States
Study Locations
More Related Trials
-
Surveillance Study of Respiratory Syncytial Virus Infection (RSV) in Subjects < 24 Months of Age
NCT01754428 ·Status: COMPLETED
-
A Study to Assess Safety, Tolerability and Immunogenicity of RSVpreF From Multidose Vials in Healthy Female Adults.
NCT06473519 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
NCT02237209 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults
NCT06067230 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV)
NCT04583280 ·Status: TERMINATED ·Phase: PHASE3
-
Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age
NCT03916185 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Idylla IFV-RSV Panel Clinical Testing
NCT02786381 ·Status: COMPLETED
-
A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection
NCT06079320 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
A Two-Part Infant Study for Early Diagnosis of Respiratory Syncytial Virus (RSV) and Evaluation of JNJ-53718678 in RSV Acute Respiratory Tract Disease
NCT04068792 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants 6 to 24 Months of Age
NCT02794870 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age
NCT03227029 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
NCT01852266 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase I Randomized, Observer-Blinded, Dose-Ranging Study in Healthy Subjects 24 to <72 Months of Age
NCT02296463 ·Status: COMPLETED ·Phase: PHASE1
-
Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and Older
NCT06251024 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of Age
NCT04520659 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
NCT01968083 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
NCT02508194 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV
NCT06102174 ·Status: TERMINATED ·Phase: PHASE1
-
Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and Children
NCT03596801 ·Status: COMPLETED ·Phase: PHASE1
-
Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine
NCT02419391 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants
NCT00686075 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age
NCT00493285 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis)
NCT00233064 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older
NCT04908683 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
NCT02040831 ·Status: COMPLETED ·Phase: PHASE1